Trading Tips Blog

Michael Burry — the investor made famous by "The Big Short" for correctly calling the 2008 housing collapse — has made a new contrarian move. He announced Wednesday he purchased a full-sized position split roughly 60% in Flutter Entertainment (NYSE: FLUT) and 40% in DraftKings (NASDAQ: DKNG). Burry bought Flutter at approximately $107 per share and DraftKings in the low-$26 range. Both sportsbooks have been under significant pressure, and that pressure, according to Burry, is exactly what makes them interesting. The ...
Read More About This

When most investors think about benefiting from the artificial intelligence boom, they picture chip makers, cloud computing giants, and software companies. But Goldman Sachs is pointing retail investors toward a very different kind of AI winner: Comfort Systems USA (NYSE: FIX), a mechanical and electrical contractor that keeps data centers cool. The bank initiated coverage of FIX on Thursday with a Buy rating and a $2,159 price target — implying 28% upside from recent prices. The thesis is straightforward. AI workloads ...
Read More About This

Remember when trading stocks meant calling your broker during business hours? Yeah, those days are long gone. Now Nasdaq is about to take things to the next level—literally around the clock. The exchange just announced it's filing papers with the SEC to launch 24-hour trading, five days a week. That's right: Monday through Friday, all day, all night, no breaks. Currently, the market opens at 9:30 a.m. and closes at 4 p.m. ET, which apparently isn't enough for the modern investor ...
Read More About This

Here's a wild story: Along the Myanmar-China border, rich collectors play a high-stakes game with rocks. These aren't just any rocks—they're jadeite boulders that *might* contain jade worth millions. The catch? You don't know until you crack them open. And by then, you've already paid full price for what could be a worthless hunk of stone. That's basically what's happening in the AI market right now, and it's a lesson worth learning before you blow your portfolio on the next ...
Read More About This

Remember when chip stocks were basically printing money? Yeah, those days just got a timeout. Thursday was the day the AI trade's favorite children decided to remind everyone that even the hottest sectors can have a bad hair day—and Broadcom's earnings report was the haircut nobody asked for. The semiconductor sector, which has been riding high on the back of AI euphoria, hit the brakes hard. Broadcom, the Nvidia partner that's been treated like the golden child of the chip world, ...
Read More About This

Remember when SpaceX was just a scrappy startup with a dream and a budget that made venture capitalists nervous? Well, those days are long gone. When Elon Musk took SpaceX public in June with a roughly $2 trillion valuation, something wild happened: thousands of regular employees—including production line workers and welders—suddenly found themselves sitting on seven-figure portfolios. During a recent interview on "The Sean Hannity Show," Musk dropped the kind of casual flex that only a guy worth a trillion dollars ...
Read More About This

Remember that story about the jade traders in Myanmar? They're out there buying these gray, ugly rocks that *might* contain millions in green jade—or might be completely worthless. The cruel part? You don't know until you crack it open and pay full price. But here's the plot twist: what if you could drill a tiny test hole first? Sample the goods before going all-in? Suddenly, you're not gambling—you're investing. That's exactly how you should think about the AI selloff happening right now. **The ...
Read More About This

Biotech doesn't follow the same rules as the rest of the market -- and that's precisely what makes it so compelling for investors who know how to read the signals. While tech stocks fret over Fed policy and inflation data, biotech trades on its own clock: FDA decisions, clinical trial results, and advisory committee votes. Right now, something interesting is happening across a handful of smaller biotech names. Institutional investors are quietly building positions -- and that pattern of smart-money ...
Read More About This